NK Cell-Based Immunotherapies in Cancer.

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Immunotherapy, particularly using immune cells, has revolutionized cancer treatment.
• Natural killer (NK) cells are crucial innate immune cells with potent anti-tumor cytotoxicity.
• NK cells recognize and eliminate tumor cells without prior sensitization.

Purpose of the Study:

• To summarize recent advancements in NK cell-based cancer immunotherapies.
• To highlight the role of genetic engineering in enhancing NK cell anti-tumor functions.
• To discuss various types of engineered NK cells and ongoing clinical trials.

Main Methods:

• Review of current research on NK cell-based immunotherapies.
• Focus on genetic engineering techniques for NK cell modification (e.g., CAR-NK cells).
• Analysis of approaches to improve NK cell number and function (cytokines, adoptive transfer, cell lines, iPSCs).

Main Results:

• Various strategies are being developed to enhance NK cell number and anti-tumor activity.
• Engineered NK cells, such as chimeric antigen receptor (CAR)-NK cells, show promise.
• NK cell-based immunotherapies are demonstrating enhanced functional specificity in clinical trials.

Conclusions:

• NK cell-based immunotherapies represent a promising strategy for malignant tumor treatment.
• Genetic engineering technologies are pivotal in developing next-generation NK cell therapies.
• Clinical trials are evaluating the safety and efficacy of these advanced NK cell treatments.